B
SYRE icon

Braidwell’s Spyre Therapeutics SYRE Stock Holding History

Braidwell’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.1M Sell
879,467
-53,356
-6% -$3.89M 2.89% 5
2026
Q1 		$47.1M Sell
932,823
-701,792
-43% -$26.5M 1.57% 21
2025
Q4 		$53.5M Sell
1,634,615
-943,789
-37% -$24.7M 1.71% 19
2025
Q3 		$43.2M Hold
2,578,404
– – 1.28% 26
2025
Q2 		$38.6M Hold
2,578,404
– – 1.32% 27
2025
Q1 		$41.6M Hold
2,578,404
– – 1.46% 30
2024
Q4 		$60M Buy
2,578,404
+388,568
+18% +$11.4M 1.78% 21
2024
Q3 		$64.4M Sell
2,189,836
-324,702
-13% -$9.04M 1.83% 23
2024
Q2 		$59.1M Buy
2,514,538
+1,999,538
+388% +$67.4M 1.85% 20
2024
Q1 		$19.5M Hold
515,000
– – 0.63% 51
2023
Q4 		$11.1M Buy
+515,000
New +$7.09M 0.41% 56

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Braidwell's SYRE Position: Q2 2026 in Review

Braidwell reduced its Spyre Therapeutics (SYRE) stake by 5.7% in Q2 2026, selling an estimated $3.89M and leaving 879,467 shares worth $78.1M. The position accounts for 2.89% of the portfolio, ranked #5.

Braidwell first reported a position in SYRE in Q4 2023 and has held it in 11 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Braidwell held 879,467 shares of Spyre Therapeutics worth $78.1M as of Q2 2026.
  • Braidwell sold 53,356 Spyre Therapeutics shares in Q2 2026, an estimated $3.89M.
  • Spyre Therapeutics made up 2.89% of Braidwell's portfolio in Q2 2026, its #5 holding.
  • Braidwell first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.